减毒霍乱弧菌疫苗株CVD 103-HgR重新获得霍乱肠毒素基因的可能性。
Potential for reacquisition of cholera enterotoxin genes by attenuated Vibrio cholerae vaccine strain CVD 103-HgR.
作者信息
Kaper J B, Michalski J, Ketley J M, Levine M M
机构信息
Division of Geographic Medicine, University of Maryland School of Medicine, Baltimore 21201.
出版信息
Infect Immun. 1994 Apr;62(4):1480-3. doi: 10.1128/iai.62.4.1480-1483.1994.
Abstract
The potential for reacquisition of ctxA genes by attenuated Vibrio cholerae O1 vaccine strain CVD 103-HgR was examined by performing a series of mating experiments under a variety of in vivo and in vitro conditions. We found no evidence that CVD 103-HgR could reacquire ctxA genes from wild-type V. cholerae O1 strains. However, if the donor V. cholerae O1 strains were genetically manipulated to add genes that allow chromosomal gene transfer, then ctxA sequences could be acquired by CVD 103-HgR. The minimal excretion of CVD 103-HgR by vaccinees and the refractoriness to reacquisition of ctxA sequences suggest that this well-tolerated, highly immunogenic live oral cholera vaccine will have a minimal environmental impact.
摘要
通过在多种体内和体外条件下进行一系列交配实验，研究了减毒霍乱弧菌O1疫苗株CVD 103-HgR重新获得ctxA基因的可能性。我们没有发现证据表明CVD 103-HgR能够从野生型霍乱弧菌O1菌株重新获得ctxA基因。然而，如果对供体霍乱弧菌O1菌株进行基因操作以添加允许染色体基因转移的基因，那么CVD 103-HgR就可以获得ctxA序列。疫苗接种者对CVD 103-HgR的最低排泄量以及对重新获得ctxA序列的难治性表明，这种耐受性良好、免疫原性高的口服活霍乱疫苗对环境的影响将降至最低。
相似文献
1
Potential for reacquisition of cholera enterotoxin genes by attenuated Vibrio cholerae vaccine strain CVD 103-HgR.
Infect Immun. 1994 Apr;62(4):1480-3. doi: 10.1128/iai.62.4.1480-1483.1994.
2
Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination.
Infect Immun. 1999 Dec;67(12):6341-5. doi: 10.1128/IAI.67.12.6341-6345.1999.
3
A review of the current status of enteric vaccines.
P N G Med J. 1995 Dec;38(4):325-31.
4
Construction of genetically marked Vibrio cholerae O1 vaccine strains.
FEMS Microbiol Lett. 1993 Jul 15;111(1):15-21. doi: 10.1111/j.1574-6968.1993.tb06355.x.
5
Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR.
Lancet. 1988 Aug 27;2(8609):467-70. doi: 10.1016/s0140-6736(88)90120-1.
6
Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children.
Lancet. 1992 Sep 19;340(8821):689-94. doi: 10.1016/0140-6736(92)92231-4.
7
Safety and immunogenicity of live oral cholera vaccine candidate CVD 110, a delta ctxA delta zot delta ace derivative of El Tor Ogawa Vibrio cholerae.
J Infect Dis. 1993 Dec;168(6):1536-40. doi: 10.1093/infdis/168.6.1536.
8
Recombinant attenuated Vibrio cholerae strains used as live oral vaccines.
Res Microbiol. 1990 Sep-Oct;141(7-8):901-6. doi: 10.1016/0923-2508(90)90128-d.
9
Biosafety aspects of the recombinant live oral Vibrio cholerae vaccine strain CVD 103-HgR.
Vaccine. 2004 Jun 23;22(19):2457-69. doi: 10.1016/j.vaccine.2003.12.033.
10
The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers.
Infect Immun. 2005 May;73(5):3018-24. doi: 10.1128/IAI.73.5.3018-3024.2005.
引用本文的文献
1
Immunogenicity and protective efficacy of a live, oral cholera vaccine formulation stored outside-the-cold-chain for 140 days.
BMC Immunol. 2020 May 25;21(1):29. doi: 10.1186/s12865-020-00360-1.
2
Fishing for vaccines against using pan-proteomic reverse vaccinology approach.
PeerJ. 2019 Jun 19;7:e6223. doi: 10.7717/peerj.6223. eCollection 2019.
3
Acute, infectious diarrhea among children in developing countries.
Semin Pediatr Infect Dis. 2004 Jul;15(3):155-68. doi: 10.1053/j.spid.2004.05.008.
4
Evaluation of a bivalent (CVD 103-HgR/CVD 111) live oral cholera vaccine in adult volunteers from the United States and Peru.
Infect Immun. 1997 Sep;65(9):3852-6. doi: 10.1128/iai.65.9.3852-3856.1997.
5
Oral immunization with attenuated vaccine strains of Vibrio cholerae expressing a dodecapeptide repeat of the serine-rich Entamoeba histolytica protein fused to the cholera toxin B subunit induces systemic and mucosal antiamebic and anti-V. cholerae antibody responses in mice.
Infect Immun. 1997 Aug;65(8):3118-25. doi: 10.1128/iai.65.8.3118-3125.1997.
6
Protective immunity against Clostridium difficile toxin A induced by oral immunization with a live, attenuated Vibrio cholerae vector strain.
Infect Immun. 1997 Jul;65(7):2941-9. doi: 10.1128/iai.65.7.2941-2949.1997.
7
The sixth and seventh cholera pandemics are due to independent clones separately derived from environmental, nontoxigenic, non-O1 Vibrio cholerae.
J Bacteriol. 1995 Jun;177(11):3191-8. doi: 10.1128/jb.177.11.3191-3198.1995.
本文引用的文献
1
Observations of the nature of genetic recombination in Vibrio cholerae.
Indian J Med Res. 1959 May;47(3):253-60.
2
Genetic recombination in Vibrio cholerae.
J Gen Microbiol. 1958 Aug;19(1):71-5. doi: 10.1099/00221287-19-1-71.
3
CTX genetic element encodes a site-specific recombination system and an intestinal colonization factor.
Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3750-4. doi: 10.1073/pnas.90.8.3750.
4
Live oral vaccines against cholera: an update.
Vaccine. 1993;11(2):207-12. doi: 10.1016/0264-410x(93)90019-t.
5
CVD110, an attenuated Vibrio cholerae O1 El Tor live oral vaccine strain.
Infect Immun. 1993 Oct;61(10):4462-8. doi: 10.1128/iai.61.10.4462-4468.1993.
6
Construction of genetically marked Vibrio cholerae O1 vaccine strains.
FEMS Microbiol Lett. 1993 Jul 15;111(1):15-21. doi: 10.1111/j.1574-6968.1993.tb06355.x.
7
Safety, immunogenicity, and transmissibility of single-dose live oral cholera vaccine strain CVD 103-HgR in 24- to 59-month-old Indonesian children.
J Infect Dis. 1993 Nov;168(5):1169-76. doi: 10.1093/infdis/168.5.1169.
8
Emergence of multiply antibiotic-resistant Vibrio cholerae in Bangladesh.
J Infect Dis. 1980 Dec;142(6):939-42. doi: 10.1093/infdis/142.6.939.
9
General Transduction in Vibrio cholerae.
Infect Immun. 1981 Feb;31(2):737-41. doi: 10.1128/iai.31.2.737-741.1981.
10
Cholera toxin genes: nucleotide sequence, deletion analysis and vaccine development.
Nature. 1983;306(5943):551-7. doi: 10.1038/306551a0.
Zotero 插件